Sarcopenia: investigation of metabolic changes and its associated mechanisms.
Energy metabolism
Fatty acid metabolism
Fatty acid oxidation
Lipid metabolism
Metabolomics
Mitochondrial metabolism
Sarcopenia
Journal
Skeletal muscle
ISSN: 2044-5040
Titre abrégé: Skelet Muscle
Pays: England
ID NLM: 101561193
Informations de publication
Date de publication:
19 01 2023
19 01 2023
Historique:
received:
10
08
2022
accepted:
13
12
2022
entrez:
19
1
2023
pubmed:
20
1
2023
medline:
24
1
2023
Statut:
epublish
Résumé
Sarcopenia is one of the most predominant musculoskeletal diseases of the elderly, defined as age-related progressive and generalized loss of muscle mass with a simultaneous reduction in muscle strength and/or function. Using metabolomics, we aimed to examine the association between sarcopenia and the plasma metabolic profile of sarcopenic patients, measured using a targeted HPLC-MS/MS platform. Plasma samples from 22 (17 men) hip fracture patients undergoing surgery (8 sarcopenic, age 81.4+6.3, and 14 non-sarcopenic, age 78.4±8.1) were analyzed. T test, fold change, orthogonal partial least squares discriminant analysis, and sparse partial least squares discriminant analysis were used for mining significant features. Metabolite set enrichment analysis and mediation analysis by PLSSEM were thereafter performed. Using a univariate analysis for sarcopenia z score, the amino acid citrulline was the only metabolite with a significant group difference after FDR correction. Positive trends were observed between the sarcopenia z score and very long-chain fatty acids as well as dicarboxylic acid carnitines. Multivariate analysis showed citrulline, non-esterified fatty acid 26:2, and decanedioyl carnitine as the top three metabolites according to the variable importance in projection using oPLS-DA and loadings weight by sPLS-DA. Metabolite set enrichment analysis showed carnitine palmitoyltransferase deficiency (II) as the highest condition related to the metabolome. We observed a difference in the plasma metabolic profile in association with different measures of sarcopenia, which identifies very long-chain fatty acids, Carn.DC and citrulline as key variables associated with the disease severity. These findings point to a potential link between sarcopenia and mitochondrial dysfunction and portraits a number of possible biochemical pathways which might be involved in the disease pathogenesis.
Sections du résumé
BACKGROUND
Sarcopenia is one of the most predominant musculoskeletal diseases of the elderly, defined as age-related progressive and generalized loss of muscle mass with a simultaneous reduction in muscle strength and/or function. Using metabolomics, we aimed to examine the association between sarcopenia and the plasma metabolic profile of sarcopenic patients, measured using a targeted HPLC-MS/MS platform.
METHODS
Plasma samples from 22 (17 men) hip fracture patients undergoing surgery (8 sarcopenic, age 81.4+6.3, and 14 non-sarcopenic, age 78.4±8.1) were analyzed. T test, fold change, orthogonal partial least squares discriminant analysis, and sparse partial least squares discriminant analysis were used for mining significant features. Metabolite set enrichment analysis and mediation analysis by PLSSEM were thereafter performed.
RESULTS
Using a univariate analysis for sarcopenia z score, the amino acid citrulline was the only metabolite with a significant group difference after FDR correction. Positive trends were observed between the sarcopenia z score and very long-chain fatty acids as well as dicarboxylic acid carnitines. Multivariate analysis showed citrulline, non-esterified fatty acid 26:2, and decanedioyl carnitine as the top three metabolites according to the variable importance in projection using oPLS-DA and loadings weight by sPLS-DA. Metabolite set enrichment analysis showed carnitine palmitoyltransferase deficiency (II) as the highest condition related to the metabolome.
CONCLUSIONS
We observed a difference in the plasma metabolic profile in association with different measures of sarcopenia, which identifies very long-chain fatty acids, Carn.DC and citrulline as key variables associated with the disease severity. These findings point to a potential link between sarcopenia and mitochondrial dysfunction and portraits a number of possible biochemical pathways which might be involved in the disease pathogenesis.
Identifiants
pubmed: 36658632
doi: 10.1186/s13395-022-00312-w
pii: 10.1186/s13395-022-00312-w
pmc: PMC9850598
doi:
Substances chimiques
Citrulline
29VT07BGDA
Fatty Acids
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2Informations de copyright
© 2023. The Author(s).
Références
EMBO J. 1996 Apr 15;15(8):1753-65
pubmed: 8617220
Toxicology. 2004 Oct 15;203(1-3):1-15
pubmed: 15363577
Biochim Biophys Acta. 2016 Jul;1862(7):1267-78
pubmed: 27020404
J Lab Clin Med. 2001 Apr;137(4):231-43
pubmed: 11283518
Science. 2005 Jul 15;309(5733):481-4
pubmed: 16020738
Endocrinology. 2008 May;149(5):2620-7
pubmed: 18276748
Bioinformatics. 2018 Dec 15;34(24):4313-4314
pubmed: 29955821
Pediatr Res. 2003 Jun;53(6):1013-8
pubmed: 12646728
Cell. 2013 Jun 6;153(6):1194-217
pubmed: 23746838
Science. 2000 Sep 29;289(5488):2363-6
pubmed: 11009425
J Gerontol A Biol Sci Med Sci. 2014 Apr;69(4):438-46
pubmed: 24085400
J Lipid Res. 2015 Oct;56(10):2029-39
pubmed: 26239049
J Clin Endocrinol Metab. 1997 Dec;82(12):4208-13
pubmed: 9398741
Mol Cell Biol. 2005 Aug;25(15):6533-45
pubmed: 16024790
Biochem J. 1985 Sep 15;230(3):683-93
pubmed: 4062873
Hepatology. 1994 Feb;19(2):471-9
pubmed: 7904981
Mol Cell Biol. 2007 Mar;27(5):1649-64
pubmed: 17189427
J Clin Endocrinol Metab. 2014 May;99(5):1675-86
pubmed: 24483154
Proc Natl Acad Sci U S A. 2006 Feb 21;103(8):2653-8
pubmed: 16477035
Aging (Albany NY). 2011 Aug;3(8):702-15
pubmed: 21832306
Endocrinology. 1980 Dec;107(6):1875-9
pubmed: 7428695
Clin Nutr. 2015 Aug;34(4):667-73
pubmed: 25103151
Mech Ageing Dev. 1981 Feb;15(2):165-76
pubmed: 7194952
Age Ageing. 2019 Jan 1;48(1):16-31
pubmed: 30312372
Nat Genet. 2008 Apr;40(4):392-4
pubmed: 18311139
Toxicol Sci. 2000 Sep;57(1):177-85
pubmed: 10966524
Exerc Sport Sci Rev. 2017 Apr;45(2):58-69
pubmed: 28098577
Lancet. 2019 Jun 29;393(10191):2636-2646
pubmed: 31171417
J Inherit Metab Dis. 1999 May;22(3):302-6
pubmed: 10384392
Proc Natl Acad Sci U S A. 2003 Jun 24;100(13):7996-8001
pubmed: 12808136
J Clin Endocrinol Metab. 2014 May;99(5):1712-21
pubmed: 24606072
Age Ageing. 2010 Jul;39(4):412-23
pubmed: 20392703
Biol Chem. 2013 Mar;394(3):393-414
pubmed: 23154422
J Chromatogr B Analyt Technol Biomed Life Sci. 2011 Mar 1;879(7-8):495-504
pubmed: 21292569
J Cell Physiol. 2021 Jan;236(1):260-272
pubmed: 32506638
Anal Chem. 2012 Feb 7;84(3):1483-90
pubmed: 22224852
J Cell Physiol. 2015 Nov;230(11):2618-25
pubmed: 25820482
PLoS One. 2017 Jan 17;12(1):e0169548
pubmed: 28095426
Dis Markers. 2019 Jul 1;2019:9140789
pubmed: 31354893
J Inherit Metab Dis. 2015 Jul;38(4):681-702
pubmed: 25687155
Hepatology. 2016 Mar;63(3):776-86
pubmed: 26638128
Endocrinology. 2008 May;149(5):2433-42
pubmed: 18187555
J Biol Chem. 2002 Jan 18;277(3):2330-5
pubmed: 11706022
Intern Med. 2017;56(7):755-762
pubmed: 28381740
J Clin Endocrinol Metab. 2021 Mar 25;106(4):e1698-e1707
pubmed: 33378445
Arch Public Health. 2014 Dec 18;72(1):45
pubmed: 25810912
Nature. 2004 May 27;429(6990):417-23
pubmed: 15164064
Pediatr Res. 2001 Apr;49(4):519-31
pubmed: 11264436
Am J Physiol Endocrinol Metab. 2009 Aug;297(2):E392-401
pubmed: 19470832